When did the court grant preliminary approval of the QVAR antitrust settlement?

The U.S. District Court for the District of Massachusetts reportedly granted preliminary approval of the $35 million Teva QVAR antitrust class action settlement on April 2, 2026. Preliminary approval authorizes the class notice program and opens the claim form. The next milestone on the court's docket is the final approval (fairness) hearing.

Who qualifies for the QVAR antitrust settlement?

You may qualify if you purchased, paid for, or reimbursed for QVAR asthma inhalers between January 1, 2015 and July 31, 2025 in one of the eligible states. The settlement covers both individual consumers (who bought QVAR out of pocket or through insurance) and third-party payors (insurers and health plans that reimbursed for QVAR prescriptions). The settlement covers 41 states plus Washington, DC; the full state list is published on the official Settlement Website.

How much could each person get from the QVAR settlement?

Individual payout amounts have not been announced. The total Settlement Fund is $35 million. Plaintiffs' attorneys reportedly plan to request up to $11.5 million in fees, leaving roughly $23.5 million before administration costs and other deductions. Each claimant's share will depend on the total number of valid claims, how much each claimant spent on QVAR during the class period, and the court-approved plan of allocation. Payments are typically distributed pro rata, so frequent QVAR buyers over many years will likely receive more than someone who filled a single prescription.

What did Teva do wrong according to the QVAR antitrust lawsuit?

The lawsuit alleges Teva used anticompetitive tactics to block or delay generic versions of QVAR asthma inhalers from reaching the market. This allegedly included product reformulations, strategic patent filings in the FDA's Orange Book, and litigation designed to extend its monopoly. The result was that consumers and insurers paid higher prices for QVAR than they would have if generics had been available sooner. Teva denies wrongdoing and agreed to settle to avoid further litigation costs.

How does the QVAR antitrust case relate to the FTC's scrutiny of Teva's Orange Book listings?

The Federal Trade Commission has previously scrutinized Teva's Orange Book patent listings for inhalers including QVAR. The Orange Book is the FDA's database of patents tied to approved drugs; brand-name manufacturers can list patents there to delay generic approval. The QVAR antitrust class action draws on a similar evidentiary basis as the FTC scrutiny — that certain QVAR Orange Book patents allegedly should not have been listed and were used to keep cheaper generic inhalers off the market. As part of the settlement, Teva reportedly agreed to withdraw certain QVAR-related patents from the Orange Book.

When will QVAR settlement payments go out?

There is no confirmed public payment date yet. With preliminary approval reportedly granted on April 2, 2026 and the claim form now live, the next milestone is the final approval (fairness) hearing. After the settlement becomes final (typically 30 days after the Final Approval Order if no appeals are filed), the Settlement Administrator can begin distributing payments. Appeals can push distribution out by 12 to 36 months. Monitor the official Settlement Website for the court-approved schedule and payment timing.

QVAR $35M Antitrust Settlement — Claim Form Live (May 2026)

Q: Is the QVAR antitrust settlement claim form live?

Yes. As of May 2026, the official QVAR antitrust settlement website at qvarantitrustsettlement.com is live and the claim form has launched. This follows the U.S. District Court for the District of Massachusetts reportedly granting preliminary approval of the $35 million Teva QVAR antitrust class action settlement on April 2, 2026. The official Settlement Website is the controlling source for the current claim filing deadline and case documents.

By Steve Levine

QVAR asthma inhaler $35 million Teva antitrust class action settlement update May 2026

Published: April 4, 2026 · Updated: May 25, 2026

Status Claims Open claim form launched May 2026 · preliminary approval reportedly granted April 2, 2026

Claim Deadline See Official Site court-approved schedule and exact claim deadline are posted at qvarantitrustsettlement.com

Settlement Fund $35 Million plus Teva's reported agreement to withdraw certain QVAR-related patents from the FDA Orange Book

Proof Required Yes QVAR purchase records (pharmacy receipts, insurance EOBs, or prescription history) supporting purchases between Jan 1, 2015 – Jul 31, 2025

What's New: QVAR Claim Form Is Live

May 25, 2026 update: The official QVAR antitrust settlement website at qvarantitrustsettlement.com is live and the claim form has launched. This follows the U.S. District Court for the District of Massachusetts reportedly granting preliminary approval of the $35 million Teva QVAR antitrust class action settlement on April 2, 2026.

This page is a news update on case status and procedural milestones. For step-by-step claim instructions, eligibility checks, payout estimates, the full eligible-state list, and the court-approved claim deadline, the official administrator site at qvarantitrustsettlement.com is the controlling source.

What Is the QVAR Antitrust Settlement About?

QVAR is a prescription corticosteroid asthma inhaler manufactured by Teva. The end-payor litigation, filed in the U.S. District Court for the District of Massachusetts, alleges that Teva used a combination of product reformulations, strategic patent filings in the FDA's Orange Book, and litigation tactics to block or delay generic competitors from entering the market. When generic versions of a brand-name drug are kept off the market, consumers and insurers have no cheaper alternative and end up paying more than they should.

In plain terms: generic inhalers that could have been available sooner were allegedly held back by Teva's actions. People with asthma who needed QVAR had to keep paying brand-name prices longer than necessary.

The FDA's "Orange Book" is a federal database listing patents tied to approved drugs. Brand-name manufacturers can list patents in the Orange Book to delay generic approval, because a generic applicant generally has to navigate around any Orange-Book-listed patent before the FDA will approve the generic. The lawsuit claims Teva listed patents in the Orange Book that should not have been there, which delayed generic companies from obtaining FDA approval for their versions of QVAR. The Federal Trade Commission has previously scrutinized some of these same Orange Book listings.

In addition to the $35 million cash fund, the settlement reportedly includes an agreement by Teva to withdraw certain QVAR-related patents from the Orange Book. That is significant beyond this settlement, because removing those patents could make it easier for generic QVAR to reach the market in the future.

Old Status vs. New Status: What Changed

For consumers who have been following the QVAR case, here is a clear before-and-after of where things stand after the May 2026 update.

Item	Old Status (April 2026)	New Status (May 2026)
Court approval stage	Settlement filed Oct 24, 2025; preliminary approval pending	Preliminary approval reportedly granted April 2, 2026
Settlement Website	qvarantitrustsettlement.com — placeholder; not fully launched	qvarantitrustsettlement.com — live
Claim Form	Not available	Live; available on the official Settlement Website
Claim Deadline	Not yet announced	Set by the Court — posted on the official Settlement Website
Final Approval Hearing	Not yet scheduled	Scheduled on the court docket — date posted on the Settlement Website
Settlement Fund	$35 million (proposed)	$35 million (preliminarily approved)
Orange Book Patent Withdrawal	Proposed as part of settlement	Part of preliminarily approved settlement terms

Who Qualifies for the QVAR Settlement?

You may qualify if you purchased, paid for, or were reimbursed for QVAR asthma inhalers between January 1, 2015 and July 31, 2025, and you lived in one of the eligible states. The settlement covers both:

• Individual consumers — people who bought QVAR out of pocket or through insurance copays
• Third-party payors — insurance companies, health plans, and other entities that reimbursed for QVAR prescriptions

The settlement reportedly covers 41 states plus Washington, DC. The full list of eligible states is published on the official Settlement Website's long-form notice. If your state is not on that list, you would not be part of this settlement class. Eligibility for end-payor antitrust settlements typically tracks state laws that allow indirect-purchaser recovery; not every state has such a law on its books.

How Much Could Each Person Get?

Individual payout amounts have not been announced. Here is what is known about the money:

The total Settlement Fund is $35 million. Plaintiffs' attorneys reportedly plan to request up to $11.5 million in fees from the fund. If the court approves that fee at the cap, approximately $23.5 million would remain before administration costs and other deductions.

How much each person gets will depend on:

• The total number of valid claims filed
• How much each claimant spent on QVAR during the class period
• The court-approved plan of allocation (typically a pro rata distribution proportional to documented purchases)

Because the class potentially includes a large number of people across 41 states over a 10-year period, individual payments will vary widely. People who bought QVAR inhalers frequently and over many years will likely receive more than someone who filled a single prescription.

What Records Do You Need to File a Claim?

QVAR end-payor claims are documented purchase claims, so the more proof you can gather, the cleaner your claim. Useful records include:

• Pharmacy receipts or printouts showing the QVAR prescription and what you paid out of pocket
• Insurance Explanation of Benefits (EOB) statements showing QVAR prescription claims and the out-of-pocket portion
• Prescription history printouts from your pharmacy (most pharmacies will print or email a year-by-year history on request)
• Health Savings Account or Flexible Spending Account statements showing QVAR purchases reimbursed through pre-tax accounts

If you no longer have receipts, contact your pharmacy and your insurer to request prescription history. Pharmacies typically retain prescription records for several years; many will provide a printable history covering multiple years on request.

What's Next in the QVAR Case

With the claim form now live, the next milestone on the court's docket is the final approval (fairness) hearing. At that hearing the Court will decide whether to grant final approval of the $35 million settlement, the distribution plan, and class counsel's fee request. Once final approval becomes "final" (after any appeal window expires), the Settlement Administrator can begin distributing payments to approved class members.

The court-approved schedule — including the final approval hearing date and the current claim filing deadline — is posted on the official Settlement Administrator's site at qvarantitrustsettlement.com. Bookmark it and check it periodically.

Watch Out for QVAR Settlement Scams

Newly-launched settlement claim forms attract scammers. The QVAR claim launch is exactly the kind of headline that triggers scam attempts targeting consumers who are trying to file. A few common-sense rules:

• Never pay a fee. Legitimate class action settlements never require an activation fee, processing fee, or "release fee" to file a claim or receive a settlement payment. Anyone asking for payment to "submit" or "expedite" your QVAR claim is running a scam.
• Never share your full Social Security Number, bank account password, or credit card number with anyone claiming to handle your QVAR settlement claim by phone, text, or email. The Settlement Administrator does not need that information to process your claim or mail your check.
• Use the official Settlement Website only: qvarantitrustsettlement.com. Type the URL directly. Be cautious of any email or text linking to a "QVAR settlement" page from a different domain.
• Be skeptical of "click here to claim your QVAR settlement" emails from unfamiliar senders.
• If you receive a check, verify it through your bank before depositing or cashing.

Other Related OCA Coverage

QVAR is one of several large pharmaceutical antitrust and pay-for-delay cases working through the courts. Class membership in one settlement does not affect eligibility for any other unrelated case.

• Tracleer (Bosentan) Pay-for-Delay Settlement — $65M end-payer pay-for-delay settlement (third-party payors only)
• Teva, Granules & Heritage Metformin NDMA Settlement — $5.55M consumer settlement covering U.S. buyers of generic metformin (Jul 2015 – Jun 2020)
• OCA database of open class action settlements — complete list of active consumer cases
• Latest class action news and updates

How Do I Find Class Action Settlements?

Find all the latest class actions you can qualify for by getting notified of new lawsuits as soon as they are open to claims:

Settlement Website: QVARAntitrustSettlement.com

File QVAR Claim — Official Site

Frequently Asked Questions About the QVAR Settlement

Is the QVAR claim form open?

Yes. As of May 2026, the official Settlement Website at qvarantitrustsettlement.com is live and the claim form has launched.

Who qualifies?

Consumers and third-party payors who purchased, paid for, or reimbursed for QVAR asthma inhalers between January 1, 2015 and July 31, 2025 in one of the 41 eligible states plus Washington, DC.

How much will I get?

Individual amounts are not yet announced. The $35 million Settlement Fund will be distributed pro rata to valid claimants after deductions for administration costs, attorneys' fees (reportedly capped at $11.5 million), and other court-approved expenses.

What is the claim deadline?

Check the official Settlement Website at qvarantitrustsettlement.com for the court-approved claim filing deadline. That site is the controlling source.

Do I need proof?

Yes. QVAR end-payor claims are documented purchase claims. Useful records include pharmacy receipts, insurance EOB statements, prescription history printouts, and HSA/FSA statements covering QVAR purchases during the class period.

When will payments go out?

No confirmed payment date yet. After the Court grants final approval and any appeal window expires, the Settlement Administrator will begin distributing payments. Best case: several weeks to several months after final approval becomes final. With appeals: 12 to 36 months.

What is the case name and court?

The litigation is the consolidated End-Payor Plaintiffs action against Teva, pending in the U.S. District Court for the District of Massachusetts. The official Settlement Website is the authoritative source for the precise case caption, lead case number, and presiding judge.

Sources

• Official Settlement Website: QVARAntitrustSettlement.com
• Reuters, "Teva agrees to pay $35 million to settle asthma inhaler antitrust lawsuit" (October 27, 2025)
• MLex coverage of preliminary approval (April 2, 2026)
• FTC letter regarding Orange Book listings for QVAR RediHaler
• May 7, 2024 Memorandum and Order, U.S. District Court for the District of Massachusetts
• Defendant: Teva Pharmaceutical Industries Ltd. and related Teva entities
• Court: U.S. District Court for the District of Massachusetts
• FDA: Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
• FTC: Drug Pricing & Competition

About This Page

This page reports on the Teva QVAR asthma inhaler antitrust class action settlement after the reported preliminary approval and claim form launch, for informational purposes. OpenClassActions.com is a consumer news site and is not the Settlement Administrator, Class Counsel, or a law firm. We do not process or decide claims. The official Settlement Website (qvarantitrustsettlement.com) and the case docket are the authoritative sources for the eligible-state list, claim deadlines, the final approval hearing date, allocation methods, and payment timing. References to "reportedly" granted preliminary approval reflect that we have relied on recent reporting; the court docket in the District of Massachusetts is the primary record.

For more class actions keep scrolling below.

Open Class Action Lawsuit and Class Action Settlement

Social Media Addiction

Status: Open

Pre-Qualify

Roblox - Investigation

Pre-Qualify Here

Submit Claim

Team Group DDR-3 DDR-4 DDR-5 DRAM Computer Memory Class Action Settlement

$1.1M Team Group RAM Settlement

Pro Rata Cash · No Proof for Up to 5 Modules

Submit Claim

File a rebate form to get a coupon, refund, rebate, or payment from this new class action settlement

$68M Google Assistant Settlement

Deadline: August 27, 2026

Submit Claim

$87.5M Beef Prices Settlement

Deadline: June 30, 2026

Submit Claim

Google Play Children's Privacy Class Action Settlement

$8.25M Google Play Kids' Privacy Settlement

Est. $40–$200 Cash · No Proof Required

Submit Claim

QVAR Settlement Update Snapshot
Status	Claims Open — Claim Form Live (May 2026)
Settlement Fund	$35,000,000 cash
Additional Relief	Teva reportedly agreed to withdraw certain QVAR-related patents from the FDA Orange Book
Attorneys' Fees Request	Up to $11,500,000 (subject to court approval)
Estimated Net Fund	Approximately $23.5 million before administration costs and other deductions
Allegation	Anticompetitive tactics — product reformulations, strategic Orange Book patent filings, and litigation — used to delay generic competition for QVAR asthma inhalers
Settlement Filed	October 24, 2025
Preliminary Approval	April 2, 2026 (reportedly granted)
Claim Form Launched	May 2026
Claim Deadline	Posted on the official Settlement Website
Final Approval Hearing	Scheduled on the court docket — date posted on the official Settlement Website
Class Period	January 1, 2015 through July 31, 2025
Eligible States	41 states plus Washington, DC (full list on the official Settlement Website)
Who Qualifies	Consumers and third-party payors who purchased, paid for, or reimbursed for QVAR inhalers during the class period in eligible states
Proof Required to File?	Yes — QVAR purchase records (pharmacy receipts, insurance EOB statements, prescription history printouts, HSA/FSA statements)
Distribution Method	Pro rata distribution based on documented QVAR purchases during the class period
Defendants	Teva Pharmaceutical Industries Ltd. and related Teva entities
Case Style	Consolidated End-Payor Plaintiffs action against Teva (precise caption on the official Settlement Website)
Court	U.S. District Court for the District of Massachusetts
Category	Antitrust / Pharmaceuticals / Asthma Inhalers / Settlement Update
Official Website	QVAR Antitrust Settlement